Each tablet contains: Mefenamic acid 500 mg.
Mefenamic acid (Gardan), a member of the fenamate family, is a non-steroidal anti-inflammatory agent for oral administration. It is available in tablets containing 500 mg of Mefenamic acid. Chemically, Mefenamic acid (Gardan) is a derivative of N-phenyl anthranilic acid.
Pharmacology: Mefenamic acid has demonstrated analgesic, antipyretic and anti-inflammatory effects. In tests of analgesia, it displays a central as well as a peripheral action. These actions appear to be via inhibition of prostaglandin-forming cyclo-oxygenase.
Following a single oral dose, Mefenamic acid is fairly rapidly absorbed.
Peak concentrations in blood plasma are observed at 2 to 4 hours after ingestion. Approximately 50% of the dose of the drug is excreted in the urine as conjugated metabolites; about 20% is recovered in the feces during the first three days after administration.
Mefenamic acid (Gardan), is used in mild to moderate pain including headache, dental pain, postoperative and postpartum pain and dysmenorrhea, in musculoskeletal and joint disorders such as osteoarthritis and rheumatoid arthritis, in menorrhagia and in children with fever and juvenile idiopathic arthritis.
Adults and children over 12 years: 1 tablet initial dose followed by half-tablet every 6 hours as needed (not to be given for longer than 7 days). Preferably administered with food.
In case of overdose, gastric lavage should be performed in a conscious patient. Intensive supportive therapy should be initiated, if necessary.
Contraindicated in patients with known hypersensitivity to Mefenamic acid, in patients with active peptic ulcer or inflammatory bowel disease, and in patients with hepatic and renal impairment. Cross sensitivity with aspirin and other NSAIDS may occur and elicit allergic symptoms such as bronchoconstriction.
Absolute contraindications: Not to be given to those patients who have history of: Stroke cerebrovascular accident (CVA); Heart attack: Myocardial infarction (MI); Coronary artery bypass graft (CABG); Uncontrolled hypertension; Congestive heart failure (CHF) NYHA II-IV.
Treatment with Mefenamic acid should not be continued longer than seven days. Mefenamic acid is not recommended for use in children, pregnant women, and nursing mothers. It should be used with caution in patients with impaired renal and liver function. Concomitant therapy with plasma protein binding drugs may require modification in dosage. If anticoagulants are being administered, the dose may need to be reduced. When discomfort occurs, Mefenamic acid (Gardan) should be discontinued and consultation with physician is advised.
The most common side effects involve the gastrointestinal system, in the form of dyspepsia, upper GIT discomfort, diarrhea or constipation, and abdominal pain.
Other reactions noted less frequently include transient abnormalities of hepatic or renal function, CNS effects including headache, drowsiness, nervousness and visual disturbances, skin rashes and urticaria. Allergic glomerulonephritis known to be associated with prostaglandin inhibitors, and reversible non-oliguric renal failure has been reported. Mefenamic Acid may give a false positive in tests for the presence of bile in the urine. Hematological effects noted with long term treatment include hemolytic anemia, agranulocytosis, pancytopenia, thrombocytopenia or thrombocytopenic purpura, and bone marrow aplasia.
Store at temperatures not exceeding 30°C.
M01AG01 - mefenamic acid ; Belongs to the class of non-steroidal antiinflammatory and antirheumatic products, fenamates.
Gardan tab 500 mg
40's (P1,072.44/pack)
Sign Out
